<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="5267"><DrugName>leuprorelin acetate</DrugName><DrugNamesKey><Name id="43047077">Enanton</Name><Name id="42989251">Enantone</Name><Name id="42757355">Leuplin</Name><Name id="42989259">Leuplin 3M DPS</Name><Name id="43067991">Leuplin PRO</Name><Name id="43109879">Leuplin SR</Name><Name id="43047072">Lucrin</Name><Name id="42989254">Lucrin Depot</Name><Name id="42757357">Lupron</Name><Name id="43047073">Lupron Depot</Name><Name id="42989257">Lupron Depot-PED</Name><Name id="43047075">Procren Depot</Name><Name id="42905527">Prostap</Name><Name id="42989252">Sixantone</Name><Name id="42989253">Trenantone</Name><Name id="42757356">leuprolide acetate</Name><Name id="42757340">leuprorelin</Name></DrugNamesKey><DrugSynonyms><Name><Value>leuprorelin</Value><Types><Type>INN</Type></Types></Name><Name><Value>Leuplin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>leuprolide acetate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Lupron</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>TAP-144</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TAP-144SR</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Prostap</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Enantone</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Sixantone</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Trenantone</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lucrin Depot</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lupron Depot-PED</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>leuprorelin SR</Value></Name><Name><Value>Leuplin 3M DPS</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lucrin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Lupron Depot</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Procren Depot</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Abbott-43818</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Enanton</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Leuplin PRO</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>leuprorelin acetate</Value></Name><Name><Value>Leuplin SR</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>53714-56-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>74381-53-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20300">Takeda Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1072507">AbbVie Inc</Company><Company id="18693">Orion Corp</Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="13601">Abbott Laboratories</Company><Company id="15931">TAP Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="5267" type="Drug"><TargetEntity id="143359" type="siDrug">Leuprolide acetate depot</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="15931" type="Company"><TargetEntity id="4297502208" type="organizationId">TAP Pharmaceutical Products Inc</TargetEntity></SourceEntity><SourceEntity id="18693" type="Company"><TargetEntity id="4295866566" type="organizationId">Orion Oyj</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="113" type="ciIndication"><TargetEntity id="N80" type="ICD10"></TargetEntity><TargetEntity id="617.0" type="ICD9"></TargetEntity><TargetEntity id="10014778" type="MEDDRA"></TargetEntity><TargetEntity id="D004715" type="MeSH"></TargetEntity><TargetEntity id="-1297427982" type="omicsDisease"></TargetEntity><TargetEntity id="546" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1233" type="ciIndication"><TargetEntity id="E30.1" type="ICD10"></TargetEntity><TargetEntity id="259.1" type="ICD9"></TargetEntity><TargetEntity id="10058084" type="MEDDRA"></TargetEntity><TargetEntity id="D011629" type="MeSH"></TargetEntity><TargetEntity id="-412584527" type="omicsDisease"></TargetEntity><TargetEntity id="529" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1700" type="ciIndication"><TargetEntity id="-125221279" type="omicsDisease"></TargetEntity><TargetEntity id="547" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1780" type="ciIndication"><TargetEntity id="10046798" type="MEDDRA"></TargetEntity><TargetEntity id="-1936558955" type="omicsDisease"></TargetEntity><TargetEntity id="2347" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3127" type="ciIndication"><TargetEntity id="D055534" type="MeSH"></TargetEntity><TargetEntity id="481" type="ORPHANET"></TargetEntity><TargetEntity id="1729" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="504" type="ciIndication"><TargetEntity id="10021460" type="MEDDRA"></TargetEntity><TargetEntity id="D007153" type="MeSH"></TargetEntity><TargetEntity id="-886084388" type="omicsDisease"></TargetEntity><TargetEntity id="1130" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="1092" type="Action"><TargetEntity id="590" type="Mechanism">GnRH (LHRH) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00881" type="ciTarget"><TargetEntity id="14970030727983" type="siTarget">Gonadotropin-releasing hormone receptor</TargetEntity><TargetEntity id="2775" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hormone dependent prostate cancer - US - Dec-1985</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="113">Endometriosis</Indication><Indication id="1233">Precocious puberty</Indication><Indication id="17">Anemia</Indication><Indication id="1780">Uterine fibroids</Indication><Indication id="276">Prostate tumor</Indication><Indication id="3127">Spinal and bulbar muscular atrophy</Indication><Indication id="3247">Hormone dependent prostate cancer</Indication><Indication id="49">Breast tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1700">Premature ovarian failure</Indication><Indication id="504">Immune deficiency</Indication></IndicationsSecondary><ActionsPrimary><Action id="1092">GNRH receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="589">Sustained release formulation</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="80">Peptide</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="753">Microparticle formulation</Technology><Technology id="750">Freeze drying</Technology><Technology id="651">Intramuscular formulation</Technology></Technologies><LastModificationDate>2019-06-24T06:49:05.000Z</LastModificationDate><ChangeDateLast>2019-04-16T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Leuprorelin acetate (leuprolide acetate;  Lupron; Lupron Depot; Lucrin; Leuplin; Prostap; Enantone; Enanton; Trenantone; 	Procren Depot; TAP-144; Leuplin PRO, Leuplin SR) is  a gonadotropin-releasing hormone analog and LHRH agonist developed and launched by &lt;ulink linkID="20300" linkType="Company"&gt;Takeda&lt;/ulink&gt;, and marketed in certain territories by &lt;ulink linkID="1072507" linkType="Company"&gt;AbbVie&lt;/ulink&gt; (following its spin-out from &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt;, and formerly &lt;ulink linkID="23077" linkType="Company"&gt;TAP&lt;/ulink&gt; before the Abbott/Takeda joint venture was dissolved) and in Nordic countries by licensee &lt;ulink linkID="18693" linkType="Company"&gt;Orion&lt;/ulink&gt; [&lt;ulink linkID="526757" linkType="Reference"&gt;526757&lt;/ulink&gt;]. Available in a number of formulations, including daily sc injection and one-, three-, four- and six-month im injections,   the products are indicated for the palliative treatment of hormone dependent prostate cancer, for the management of endometriosis (including pain relief and reduction of endometriotic lesions),  for the improvement of anemia in patients with uterine fibroids and for the treatment of myoma of the uterus. Depot formulation dosages are also indicated for pediatric patients (Lupron Depot-PED) with central precocious puberty. The product is  additionally approved in  Japan as an adjuvant therapy for premenopausal breast cancer, and for the suppression of progression of spinal and bulbar  muscular atrophy [&lt;ulink linkID="504754" linkType="Reference"&gt;504754&lt;/ulink&gt;], [&lt;ulink linkID="504758" linkType="Reference"&gt;504758&lt;/ulink&gt;], [&lt;ulink linkID="504762" linkType="Reference"&gt;504762&lt;/ulink&gt;], [&lt;ulink linkID="1267452" linkType="Reference"&gt;1267452&lt;/ulink&gt;], [&lt;ulink linkID="1901564" linkType="Reference"&gt;1901564&lt;/ulink&gt;], [&lt;ulink linkID="1963782" linkType="Reference"&gt;1963782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;For prostate cancer, the drug is available as injection (7.5 mg), or as 3- (22.5 mg) or 4-month (30 mg) depot injections. A 6-month (45 mg) depot formulation for prostate cancer is also available in Europe and the US. For endometriosis and anemia associated with fibroids, the product is available as injection (3.75 mg), or as a 3-month depot injection (11.25 mg). For precocious puberty, the drug is available as 7.5, 11.25 and 15 mg depot injections for 1- month administration and 11.25 and 30 mg depot injections for 3-month administration [&lt;ulink linkID="1234882" linkType="Reference"&gt;1234882&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Leuprorelin was first approved for prostate cancer in 1985; the  7.5 mg depot injection was approved for prostate cancer in 1989 [&lt;ulink linkID="969199" linkType="Reference"&gt;969199&lt;/ulink&gt;]. The 22.5 mg 3-month depot formulation was launched for prostate cancer in 1995 [&lt;ulink linkID="969199" linkType="Reference"&gt;969199&lt;/ulink&gt;], and in July 1997, TAP received FDA clearance to market the 4-month depot for prostate cancer [&lt;ulink linkID="275052" linkType="Reference"&gt;275052&lt;/ulink&gt;]. A 6-month depot formulation was launched in the EU in January 2009 [&lt;ulink linkID="1101416" linkType="Reference"&gt;1101416&lt;/ulink&gt;]. In April 2011, Takeda received approval for PROSTAP 3 DCS 11.25 mg prolonged-release suspension for injection in pre-filled syringe in Ireland [&lt;ulink linkID="1405891" linkType="Reference"&gt;1405891&lt;/ulink&gt;]. In June 2011, a 6-month depot formulation for prostate cancer was approved in the US [&lt;ulink linkID="1201383" linkType="Reference"&gt;1201383&lt;/ulink&gt;]. In February 2012, a phase III trial of the 6-month depot formulation  began in Japan in patients with prostate cancer [&lt;ulink linkID="1267404" linkType="Reference"&gt;1267404&lt;/ulink&gt;]; in September 2014, the company filed for approval of the 6-month depot formulation in Japan [&lt;ulink linkID="1606838" linkType="Reference"&gt;1606838&lt;/ulink&gt;]; in January 2014, Japanese approval was expected in fiscal year 2014 [&lt;ulink linkID="1524161" linkType="Reference"&gt;1524161&lt;/ulink&gt;]. In December 2015, a 6-month (22.5 mg) depot formulation for prostate cancer was launched in Japan [&lt;ulink linkID="1721274" linkType="Reference"&gt;1721274&lt;/ulink&gt;], [&lt;ulink linkID="1766217" linkType="Reference"&gt;1766217&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 1995, the drug was approved for anemia caused by  uterine leiomyomata in women who fail iron therapy [&lt;ulink linkID="1251723" linkType="Reference"&gt;1251723&lt;/ulink&gt;]. In March 1997, the 3-month  formulation was approved in the US for the treatment of anemia caused by fibroids, and  endometriosis [&lt;ulink linkID="237252" linkType="Reference"&gt;237252&lt;/ulink&gt;], [&lt;ulink linkID="969199" linkType="Reference"&gt;969199&lt;/ulink&gt;].  At that time, the pediatric formulation, Lupron Depot-PED, was approved in the US for central precocious puberty [&lt;ulink linkID="177615" linkType="Reference"&gt;177615&lt;/ulink&gt;], [&lt;ulink linkID="303924" linkType="Reference"&gt;303924&lt;/ulink&gt;].   Lupron Depot-PED was launched for the treatment of central precocious puberty in Japan and Western Europe in 1998 [&lt;ulink linkID="311700" linkType="Reference"&gt;311700&lt;/ulink&gt;]. By March 2006, leuprorelin had been launched for the treatment of endometriosis and myoma of the uterus  in Europe  [&lt;ulink linkID="659000" linkType="Reference"&gt;659000&lt;/ulink&gt;]. In April 2011, Takeda received approval for PROSTAP 3 DCS 11.25 mg rolonged-release suspension for injection in pre-filled syringe in Ireland for the treatment of uterine fibroids and  endometriosis [&lt;ulink linkID="1405891" linkType="Reference"&gt;1405891&lt;/ulink&gt;].  In May 2011, the Leuplin 1.88 and 3.75 formulations were approved in Japan for the treatment of central precocious puberty [&lt;ulink linkID="1193289" linkType="Reference"&gt;1193289&lt;/ulink&gt;]. In August 2011, two new strengths of the 3-month depot (11.25 mg and 30 mg) were also approved in the US for central precocious puberty; at that time, launch was expected later that month [&lt;ulink linkID="1215423" linkType="Reference"&gt;1215423&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2017, leuprorelin acetate 11.25 mg injection kit was approved in Japan for the suppression of progression of spinal and bulbar  muscular atrophy. It is presumed that Japanese launch in this setting occurred immediately after approval [&lt;ulink linkID="1963782" linkType="Reference"&gt;1963782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A 3-month depot formulation was approved in Japan for the  treatment of premenopausal breast cancer in August 2005 [&lt;ulink linkID="636690" linkType="Reference"&gt;636690&lt;/ulink&gt;]. In September 2014, Takeda filed for approval of a 6-month depot formulation to treat premenopausal breast cancer, which was expected to be approved and launched in fiscal 2015 [&lt;ulink linkID="1598980" linkType="Reference"&gt;1598980&lt;/ulink&gt;]. In December 2015, a 6-month (22.5 mg) depot formulation for premenopausal breast cancer was launched in Japan [&lt;ulink linkID="1721274" linkType="Reference"&gt;1721274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Takeda had planned to introduce a 12-month, depot formulation, which was in phase III trials in 1999 [&lt;ulink linkID="281357" linkType="Reference"&gt;281357&lt;/ulink&gt;]; however, no further development has been reported.&lt;/para&gt;&lt;para&gt;Previously, the 3-month depot formulation was being investigated for its ability to enhance immune function in patients undergoing autologous hematopoietic stem cell transplant (HSCT); data from a phase II study were presented in December 2010 [&lt;ulink linkID="1151683" linkType="Reference"&gt;1151683&lt;/ulink&gt;]; however, no further development has been reported on the indication since that time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In the US, the 3.75 mg formulation is covered by &lt;ulink linkID="IN2172221" linkType="Patent"&gt;US-05575987&lt;/ulink&gt; and &lt;ulink linkID="IN2533791" linkType="Patent"&gt;US-05716640&lt;/ulink&gt;, which expired in September 2013, and &lt;ulink linkID="IN2400639" linkType="Patent"&gt;US-05631021&lt;/ulink&gt;, which expired in May 2014 [&lt;ulink linkID="1391303" linkType="Reference"&gt;1391303&lt;/ulink&gt;]. New strength exclusivity for the 6-month 45 mg version expired in June 2014. The formulation patent &lt;ulink linkID="IN2722310" linkType="Patent"&gt;US-06036976&lt;/ulink&gt; expires in December 2016.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Depot formulations&lt;/subtitle&gt;By April 2006, the FDA had received an ANDA with a Paragraph IV certification for injectable leuprorelin (depot) at 7.5 mg/vial [&lt;ulink linkID="663902" linkType="Reference"&gt;663902&lt;/ulink&gt;]. By July 2017, no generic version of the depot formulations had been approved [&lt;ulink linkID="1942586" linkType="Reference"&gt;1942586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Daily formulation&lt;/subtitle&gt;In August 1998, the FDA granted approval to &lt;ulink linkID="24538" linkType="Company"&gt;Sandoz&lt;/ulink&gt;  for its generic version of leuprorelin for daily sc injections [&lt;ulink linkID="1756131" linkType="Reference"&gt;1756131&lt;/ulink&gt;]. By April 2016, Sandoz had launched its generic version of leuprorelin in the US [&lt;ulink linkID="1755973" linkType="Reference"&gt;1755973&lt;/ulink&gt;] &lt;/para&gt;&lt;para&gt;In March 2009, the FDA granted approval to &lt;ulink linkID="27561" linkType="Company"&gt;Sun Pharmaceutical Industries&lt;/ulink&gt; for its generic leuprorelin 1 mg/0.2 ml for daily sc injection [&lt;ulink linkID="1036857" linkType="Reference"&gt;1036857&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In February 2014, &lt;ulink linkID="1019817" linkType="Company"&gt;ASKA Pharmaceutical&lt;/ulink&gt; launched its generic version of the drug; the generic would be distributed by Takeda [&lt;ulink linkID="1697190" linkType="Reference"&gt;1697190&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;The drug was first approved for prostate cancer in 1985; the  7.5 mg depot injection was approved for prostate cancer in 1989. The 22.5 mg 3-month depot was launched in prostate cancer in 1995 [&lt;ulink linkID="969199" linkType="Reference"&gt;969199&lt;/ulink&gt;]. In July 1997, TAP received FDA clearance to market a 4-month, 30 mg, depot formulation for treatment of advanced prostate cancer [&lt;ulink linkID="275052" linkType="Reference"&gt;275052&lt;/ulink&gt;]. By March 2010, an sNDA had been submitted for a 6-month depot formulation of leuprorelin for prostate cancer, which was accepted for review by the FDA that month [&lt;ulink linkID="1081659" linkType="Reference"&gt;1081659&lt;/ulink&gt;]. In June 2011, a 6-month, 45 mg depot formulation was approved for advanced prostate cancer; at that time, Abbott expected to launch the formulation later that month [&lt;ulink linkID="1201383" linkType="Reference"&gt;1201383&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Anemia&lt;/subtitle&gt;In March 1995, the drug was approved for anemia caused by  uterine leiomyomata in women who fail iron therapy [&lt;ulink linkID="1251723" linkType="Reference"&gt;1251723&lt;/ulink&gt;]. In March 1997, a 3-month depot formulation was approved in the US for the treatment of anemia caused by fibroids [&lt;ulink linkID="237252" linkType="Reference"&gt;237252&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Central precocious puberty&lt;/subtitle&gt;In July 1997, a 1-month injectable formulation, Lupron Depot-PED, was approved in the US for the treatment of central precocious puberty [&lt;ulink linkID="177615" linkType="Reference"&gt;177615&lt;/ulink&gt;], [&lt;ulink linkID="303924" linkType="Reference"&gt;303924&lt;/ulink&gt;]. In August 2011, US approval was also granted for two new strengths of the 3-month formulation of Lupron Depot-PED (11.25 mg and 30 mg); at that time, launch of the formulations was expected later that month [&lt;ulink linkID="1215423" linkType="Reference"&gt;1215423&lt;/ulink&gt;]. In October 2011, the FDA approved an sNDA for the 1-month formulation to include long-term data in its label for central precocious puberty [&lt;ulink linkID="1234441" linkType="Reference"&gt;1234441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Endometriosis, precocious puberty and uterine fibrosis&lt;/subtitle&gt;In January 2003, the drug was launched in Sweden [&lt;ulink linkID="1412341" linkType="Reference"&gt;1412341&lt;/ulink&gt;]. By March 2006, leuprorelin had been granted approval for the treatment of endometriosis and myoma of the uterus in women in the Nordic countries  [&lt;ulink linkID="659000" linkType="Reference"&gt;659000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, the 3-month formulation was launched in France for endometriosis and precocious puberty [&lt;ulink linkID="1353046" linkType="Reference"&gt;1353046&lt;/ulink&gt;]. In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1384513" linkType="Reference"&gt;1384513&lt;/ulink&gt;]. In July 2005, the drug was launched in Norway [&lt;ulink linkID="1457966" linkType="Reference"&gt;1457966&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In March 1989, the drug was approved in the Netherlands [&lt;ulink linkID="1429807" linkType="Reference"&gt;1429807&lt;/ulink&gt;], and subsequently launched [&lt;ulink linkID="1429809" linkType="Reference"&gt;1429809&lt;/ulink&gt;]. In October 1991, the drug was approved in Denmark and subsequently launched [&lt;ulink linkID="1426496" linkType="Reference"&gt;1426496&lt;/ulink&gt;]. In January 1992, the drug was approved in Iceland [&lt;ulink linkID="1452697" linkType="Reference"&gt;1452697&lt;/ulink&gt;]. In March 1994, the drug was launched in Switzerland [&lt;ulink linkID="1595804" linkType="Reference"&gt;1595804&lt;/ulink&gt;]. By 2002, licensee Orion Corp had been marketing leuprorelin as Enanton in Nordic countries for prostate cancer [&lt;ulink linkID="526757" linkType="Reference"&gt;526757&lt;/ulink&gt;], [&lt;ulink linkID="613227" linkType="Reference"&gt;613227&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2003, the drug was launched in Sweden [&lt;ulink linkID="1412341" linkType="Reference"&gt;1412341&lt;/ulink&gt;]. A 6-month depot formulation for prostate cancer  was filed in Germany in June 2005, in Italy in October 2005, and in France in November 2005 [&lt;ulink linkID="615297" linkType="Reference"&gt;615297&lt;/ulink&gt;], [&lt;ulink linkID="671230" linkType="Reference"&gt;671230&lt;/ulink&gt;]; approval was granted in March 2008 [&lt;ulink linkID="910172" linkType="Reference"&gt;910172&lt;/ulink&gt;].   In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1384513" linkType="Reference"&gt;1384513&lt;/ulink&gt;]. In July 2005, the drug was launched in Norway [&lt;ulink linkID="1457966" linkType="Reference"&gt;1457966&lt;/ulink&gt;]. In July and September 2007, respectively approval was granted in Finland and Sweden for the 6-month depot formulation of leuprorelin for prostate cancer [&lt;ulink linkID="888585" linkType="Reference"&gt;888585&lt;/ulink&gt;]. In May 2008 it was approved in Austria, and in July 2008 approval was granted in Germany [&lt;ulink linkID="930001" linkType="Reference"&gt;930001&lt;/ulink&gt;]. In January 2009, the 6-month formulation was launched in Finland,  Sweden, France and Germany, and launch in Austria followed in March 2009 [&lt;ulink linkID="1101416" linkType="Reference"&gt;1101416&lt;/ulink&gt;]. In November 2006, the 3-month formulation was launched in France [&lt;ulink linkID="1353046" linkType="Reference"&gt;1353046&lt;/ulink&gt;]. I&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In March 2001, an injectable 3-month depot formulation, Leuplin 3M DPS, for the potential treatment of prostate cancer was filed by Takeda in Japan [&lt;ulink linkID="459802" linkType="Reference"&gt;459802&lt;/ulink&gt;], [&lt;ulink linkID="460177" linkType="Reference"&gt;460177&lt;/ulink&gt;], this was approved in July 2002, and launched in August 2002 [&lt;ulink linkID="474529" linkType="Reference"&gt;474529&lt;/ulink&gt;]. In September 2014, the company filed for approval of the 6-month formulation [&lt;ulink linkID="1606838" linkType="Reference"&gt;1606838&lt;/ulink&gt;]. In January 2014, Japanese approval was expected in the fiscal year 2014 [&lt;ulink linkID="1524161" linkType="Reference"&gt;1524161&lt;/ulink&gt;].   In August 2015, the drug application for a 22.5 mg injection kit  for prostate cancer was recommended for approval by the  second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council in Japan [&lt;ulink linkID="1690724" linkType="Reference"&gt;1690724&lt;/ulink&gt;]. In September 2015, the 22.5 mg injection kit for the treatment of prostate cancer was approved in Japan [&lt;ulink linkID="1698749" linkType="Reference"&gt;1698749&lt;/ulink&gt;]; in December 2015, the 22.5 mg injection kit was launched in Japan [&lt;ulink linkID="1721274" linkType="Reference"&gt;1721274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In February 2004, a 3-month depot formulation was filed by Takeda in Japan for the potential treatment of premenopausal breast cancer [&lt;ulink linkID="585386" linkType="Reference"&gt;585386&lt;/ulink&gt;]. Approval for this formulation was granted  in August 2005 [&lt;ulink linkID="636690" linkType="Reference"&gt;636690&lt;/ulink&gt;]. In March 2012, a Japanese filing for the 6-month depot formulation to treat premenopausal breast cancer was expected in 2H14 [&lt;ulink linkID="1284100" linkType="Reference"&gt;1284100&lt;/ulink&gt;]. In September 2014, Takeda filed for approval of the 6-month formulation, which was expected to be approved and launched in 2015 [&lt;ulink linkID="1598980" linkType="Reference"&gt;1598980&lt;/ulink&gt;]. In August 2015, the drug application for a 22.5 mg injection kit  for premenopausal breast cancer was recommended for approval by the second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council in Japan [&lt;ulink linkID="1690724" linkType="Reference"&gt;1690724&lt;/ulink&gt;]. In September 2015, the 22.5 mg injection kit for the treatment of premenopausal breast cancer was approved in Japan [&lt;ulink linkID="1698749" linkType="Reference"&gt;1698749&lt;/ulink&gt;]; in December 2015, the 22.5 mg injection kit was launched in Japan [&lt;ulink linkID="1721274" linkType="Reference"&gt;1721274&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Central precocious puberty&lt;/subtitle&gt;The product was approved for the treatment of central precocious puberty in Japan in 1994, and had been launched for this indication by February 1999 [&lt;ulink linkID="311700" linkType="Reference"&gt;311700&lt;/ulink&gt;], [&lt;ulink linkID="1151681" linkType="Reference"&gt;1151681&lt;/ulink&gt;]. In November 2010, Takeda submitted an application to the Japanese Ministry of Health, Labor and Welfare for  its Leuplin 1.88 and 3.75 formulations [&lt;ulink linkID="1151681" linkType="Reference"&gt;1151681&lt;/ulink&gt;]. In May 2011, the Leuplin 1.88 and 3.75 formulations were approved in Japan for the treatment of central precocious puberty [&lt;ulink linkID="1193289" linkType="Reference"&gt;1193289&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Spinobulbar muscular atrophy&lt;/subtitle&gt;By August 2017, the drug was granted Orphan drug designation for the treatment of spinobulbar muscular atrophy [&lt;ulink linkID="1951513" linkType="Reference"&gt;1951513&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2017, a filing had been submitted in Japan for the approval of leuprorelin for the treatment of spinobulbar muscular atrophy [&lt;ulink linkID="1947193" linkType="Reference"&gt;1947193&lt;/ulink&gt;]; in August 2017, the Japanese MHLW's first committee on PAFSC met to discuss the filing [&lt;ulink linkID="1951513" linkType="Reference"&gt;1951513&lt;/ulink&gt;]. In August 2017, leuprorelin acetate 11.25 mg injection kit was approved in Japan for the suppression of progression of spinal and bulbar  muscular atrophy based mainly on data from investigator-initiated clinical trials that examined the efficacy and safety of the product for that indication. It is presumed that launch in this setting occurred immediately after approval [&lt;ulink linkID="1963782" linkType="Reference"&gt;1963782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In March 2003, the drug was approved in China [&lt;ulink linkID="1263001" linkType="Reference"&gt;1263001&lt;/ulink&gt;]; by February 2012, it had been launched in China for prostate cancer, breast cancer, precocious puberty, endometriosis and uterine fibroids [&lt;ulink linkID="1263002" linkType="Reference"&gt;1263002&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By  2007, the drug had been launched in Korea for the treatment of  prostate cancer [&lt;ulink linkID="938960" linkType="Reference"&gt;938960&lt;/ulink&gt;]. By June 2007, Abbott had obtained approval in Korea for the drug for use in  stimulation for in vitro fertilization [&lt;ulink linkID="938960" linkType="Reference"&gt;938960&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2012, the Australian Therapeutic Goods Administration (TGA) designated AbbVie's leuprolide acetate (Lucrin) an Orphan drug for the treatment of central precocious puberty [&lt;ulink linkID="1362396" linkType="Reference"&gt;1362396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1992, the drug was approved in Taiwan as a sustained depot subcutaneous formulation [&lt;ulink linkID="1784316" linkType="Reference"&gt;1784316&lt;/ulink&gt;]. By June 2009, the product had been launched in Taiwan by Takeda for the treatment of prostate tumor, endometriosis, central precocious puberty, uterine fibroids and premenopausal breast tumor [&lt;ulink linkID="1784314" linkType="Reference"&gt;1784314&lt;/ulink&gt;], [&lt;ulink linkID="1784315" linkType="Reference"&gt;1784315&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In May 2010, the FDA was conducting a safety review of commonly used prostate cancer drugs. The preliminary analysis of several studies suggested an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists. The FDA advised that patients receiving a GnRH agonist should be monitored. If heart disease risk was detected at the end of the analysis, the FDA would add a black box warning to GnRH agonists, including goserelin [&lt;ulink linkID="1095542" linkType="Reference"&gt;1095542&lt;/ulink&gt;]; in October 2010, the FDA requested a labeling update to include the potential risk of heart disease and diabetes [&lt;ulink linkID="1141052" linkType="Reference"&gt;1141052&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In a phase IV  study of patients with endometriosis (n=21), Lupron depot 3-month 11.25 mg was comparable to monthly Lupron depot 3.75 mg in relieving the clinical signs/symptoms of endometriosis. In both treatment groups, suppression of menses was achieved in 100% of the patients who remained in the study for at least 60 days [&lt;ulink linkID="504761" linkType="Reference"&gt;504761&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In May 2018, clinical data from an open randomized phase III study which assessed the impact of transient androgen deprivation therapy with leuprorelin LP versus active surveillance (AS) on the histological progression of indolent prostate cancer were presented at the AUA Annual Meeting in San Francisco, CA. Among 115 eligible men from 22 sites included were randomized to arm A (n = 58):  AS after a single sc injection of leuprorelin LP 11.25 mg and arm B (n = 57): usual AS. At 12 month, the number of negative biopsies was statistically different (p = 0.03) between arm A (53%) and arm B (32%; main endpoint). There were no serious adverse events related to the study drug reported [&lt;ulink linkID="2036357" linkType="Reference"&gt;2036357&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May/June 2014,  data from the randomized, RADAR trial in patients (n = 1071) with locally advanced prostate cancer, were presented at the 50th ASCO meeting in Chicago, IL. Short-term (6 months) neo-adjuvant androgen suppression (AS) using leuprolide (22.5 mg intramuscular (im), every 3 months) and radiation (STAS) either alone, or followed by intermediate term (12 months) AS (ITAS) (22.5 mg im every 3 months), or in combination with 18 months of zoledronate (4 mg iv every 3 months), increased bony progression SHR 1.85 and reduced prostate specific antigen progression (0.71) and secondary therapeutic intervention SHR (0.67)  compared to the STAS group  [&lt;ulink linkID="1561178" linkType="Reference"&gt;1561178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2012, enrollment in a multicenter, randomized, open-label, comparative, phase III trial evaluating the safety, efficacy, pharmacokinetics and hormone dynamics of a 6-month depot formulation in patients with prostate cancer (expected n = 160) began in Japan. The primary endpoint was the suppression rate of serum testosterone to castrate level [&lt;ulink linkID="1267404" linkType="Reference"&gt;1267404&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In an open-label, multicenter clinical study of Lupron depot-4 Month, 49 patients with stage D2 prostatic adenocarcinoma were enrolled. In the majority of patients, testosterone levels increased &amp;gt; 50% above  baseline during the first week. Mean serum testosterone subsequently suppressed to castrate levels within 30 days of the first injection in 94% of patients and within 43 days in all 49 patients during an initial 32-week treatment period.  One escape from suppression was noted at week 16. Objective tumor response analysis showed no progression  in 86% of patients at week 16, and in 77%  of patients at week 32. Local disease improved or remained stable in all patients evaluated at week 32. For patients with elevated baseline PSA, 50% had a normal PSA at week 16 [&lt;ulink linkID="504760" linkType="Reference"&gt;504760&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In clinical studies with the 3-month depot, serum testosterone was suppressed to castrate within 30 days in 95% of patients and within an additional 2 weeks in three patients. Two patients did not suppress for 15 and 28 weeks, respectively. Suppression was maintained in all of these patients with the exception of transient minimal testosterone elevations in one of them, and in another an increase in serum testosterone to above the castrate range was recorded during the 12-h observation period after a subsequent injection. An 85% rate of no progression was achieved during the initial 24 weeks of treatment. A decrease from baseline in serum PSA of &amp;gt;90% was reported in 71% of the patients and a change to within the normal range in 63% of the patients [&lt;ulink linkID="504759" linkType="Reference"&gt;504759&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In an open-label, multicenter clinical study of Lupron depot 7.5 mg, 56 patients with stage D2 prostatic adenocarcinoma  were enrolled, and administered a 7.5 mg depot formulation of leuprolide injected once every 4 weeks. Serum testosterone suppressed to the castrate range within 30 days of the initial depot injection in 94% of patients for whom testosterone suppression was achieved and within 66 days in all 54 patients. Mean serum testosterone suppressed to castrate level by week 3.  Serum testosterone was minimally above the castrate range on a single occasion for 4 other patients. Objective tumor response analysis showed no progression in 77% of patients at week 12, and in 84% of patients at week 24. Local disease improved or remained stable in all patients evaluated at week 12 and in 98% of patients elevated at week 24. PAP normalized or decreased at week 12 and 24 in the majority of patients with elevated baseline PAP [&lt;ulink linkID="504754" linkType="Reference"&gt;504754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endometriosis and fibroids&lt;/subtitle&gt; In controlled  studies in endometriosis, Lupron depot 3.75 mg monthly for 6 months was comparable to &lt;ulink linkID="52529" linkType="Drug"&gt;danazol&lt;/ulink&gt; 800 mg/day in relieving the clinical sign/symptoms of endometriosis (pelvic pain, dysmenorrhea, dyspareunia, pelvic tenderness and induration) and in reducing the size of endometrial implants as evidenced by laparoscopy.  The formulation induced amenorrhea in 74% and 98% of the patients after the first and second treatment months, respectively. Most of the remaining patients reported episodes of only light bleeding or spotting. In the first, second and third post-treatment months, normal menstrual cycles resumed in 7%, 71% and 95% of patients, respectively, excluding those who became pregnant [&lt;ulink linkID="504758" linkType="Reference"&gt;504758&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In controlled  trials in fibroids,  Lupron depot 3.75 mg for 3 or 6 months decreased uterine and fibroid volume,  allowing for relief of clinical symptoms (abdominal bloating, pelvic pain and pressure). Excessive vaginal bleeding (menorrhagia and menometrorrhagia) decreased, resulting in improvement in hematologic parameters. In three clinical trials, enrollment was not based on hematologic status. Mean uterine volume decreased by 41% and myoma volume decreased by 37% at final visit as evidenced by ultrasound or MRI. These patients also experienced a decrease in symptoms including excessive vaginal bleeding and pelvic discomfort. A total of 95% of  patients became amenorrheic with 61%, 25% and 4% experiencing amenorrhea during the first, second, and third treatment months respectively. In another controlled  study, enrollment was based on hematocrit &amp;lt; 30% and/or hemoglobin &amp;lt; 10.2 g/dl. Administration of Lupron depot 3.75 mg, concomitantly with iron, produced an increase of &amp;gt; 6% hematocrit and &amp;gt; 2 g/dl hemoglobin in 77% of patients at 3 months. The mean change in hematocrit was 10.1% and the mean change in hemoglobin was 4.2 g/dL [&lt;ulink linkID="504758" linkType="Reference"&gt;504758&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Central precocious puberty&lt;/subtitle&gt;In December 2008, an open-label, non-randomized, parallel assigned, multicenter, phase III trial (&lt;ulink linkID="45743" linkType="Protocol"&gt;NCT00667446&lt;/ulink&gt;; L-CP07-177) was initiated in the US in children (n = 72) with central precocious puberty to evaluate the safety of leuprolide acetate 11.25 and 30 mg formulations. In January 2013, the trial was completed [&lt;ulink linkID="1725877" linkType="Reference"&gt;1725877&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, data from a phase III study of two formulations of leuprolide in GnRHa-treatment naive and experienced children (n = 84) with central precocious puberty  were presented at the 94th Annual Meeting of the Endocrine Society in Houston, TX. In a subset of 48 children, the mean leuprolide concentrations remained constant and were dose-proportional following both doses from week 4 to 12; the mean 12-week leuprolide concentrations were similar between both groups following first and second injections. Age and weight showed no statistically significant effect on the outcomes. Although the probability of luteinizing hormone (LH) suppression was higher with higher concentrations of leuprolide, both doses provided mean LH suppression levels &amp;lt; 4 mIU/ml [&lt;ulink linkID="1303164" linkType="Reference"&gt;1303164&lt;/ulink&gt;]. In June 2014, further data were presented from this study (&lt;ulink linkID="45745" linkType="Protocol"&gt;NCT00635817&lt;/ulink&gt;)  in 42 patients at the 16th ICE/96th ENDO Joint conference in Chicago, IL. In the 11.25 and 30 mg groups, 81 and 100% of subjects showed rate of suppression (peak-stimulated luteinizing hormone &amp;lt; 4 IU/l) over the whole 6-month study period, respectively. Overall, transitioning subjects from the 1-month depot formulation to the 3-month depot formulation decreased the number of injections, physical visits and blood tests [&lt;ulink linkID="1571253" linkType="Reference"&gt;1571253&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By October 2011, data from an open-label, 55-patient trial showed that the drug suppressed clinical signs and symptoms of puberty and normalized growth rates. In the post-treatment follow-up period, in which 40 patients enrolled, puberty resumed 6 months after treatment stopped and 87.9% achieved LH levels in the puberty range. In a 20-female patient post-treatment survey, 80% had normal menstrual cycles, and 7 women reported pregnancies [&lt;ulink linkID="1234441" linkType="Reference"&gt;1234441&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In children with central precocious puberty, Lupron reduces basal gonadotropins to prepubertal levels. A measurable increase in body length can be noted since the epiphyseal plates do close prematurely. Reproductive organs  return to a prepubertal state, and menses, if present, cease [&lt;ulink linkID="504762" linkType="Reference"&gt;504762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Immune deficiency&lt;/subtitle&gt;In December 2010, data from a phase II study of leuprorelin in patients undergoing HSCT were presented at the 52nd ASH meeting in Orlando, FL. The study was terminated early due to slow patient enrollment; however, in evaluable patients (n = 18), leuprorelin significantly improved IgG1 and IgM responses at 1 month post-vaccination compared with pre-vaccination. At 6 months, a significant increase in circulating naive CD4-positive, TCR rearrangement excision circle-positive T cells was observed in  leuprolide acetate-treated patients compared with placebo-treated patients. Early disease progression was observed in 11 and 33% of patients treated with leuprolide acetate and placebo, respectively; there was no significant difference in the time to engraftment between the groups   [&lt;ulink linkID="1151683" linkType="Reference"&gt;1151683&lt;/ulink&gt;]. No further development has been reported on this indication since that time.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;In February 2012, enrollment in a multicenter, randomized, open-label, comparative, phase III trial evaluating the safety, efficacy, pharmacokinetics and hormone dynamics of a 6-month depot formulation in patients with premenopausal breast cancer (expected n = 160) began in Japan. The primary endpoint was the suppression rate of serum estradiol to menopausal level [&lt;ulink linkID="1267404" linkType="Reference"&gt;1267404&lt;/ulink&gt;]. In December 2015, clinical data from the 96-week, parallel-group comparison trial (&lt;ulink linkID="85434" linkType="Protocol"&gt;NCT01546649&lt;/ulink&gt;) were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX.  Serum E2 suppression rate (primary endpoint) based on the menopause level (&amp;lt;/= 30 pg/ml) from 4 to 48 weeks after the first administration was 97.6 and 96.4 for  leuprorelin acetate 6 mg and 3 mg groups, respectively, thereby indicating that leuprorelin acetate 6 mg was non-inferior in suppressing serum E2 levels to 3 mg. With leuprorelin acetate 6 mg, a double-peak pharmacokinetic profile and sustained release of the drug for 24 weeks were observed [&lt;ulink linkID="1721794" linkType="Reference"&gt;1721794&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In preclinical studies, leuprorelin implants were implanted sc in  dogs. Testosterone levels were maintained below 0.5 mg/ml for 19 weeks by the 18 mg formulation and for 26 weeks by the 27.5 mg formulation. No toxicity or mutagenicity was detected in rats, dogs and monkeys [&lt;ulink linkID="496068" linkType="Reference"&gt;496068&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="XQ">Nordic countries</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="659000" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1457966" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3127">Spinal and bulbar muscular atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-28T00:00:00.000Z</StatusDate><Source id="1963782" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-02-01T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-30T00:00:00.000Z</StatusDate><Source id="1784315" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="XQ">Nordic countries</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="659000" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-30T00:00:00.000Z</StatusDate><Source id="1784315" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-30T00:00:00.000Z</StatusDate><Source id="1784315" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-07-01T00:00:00.000Z</StatusDate><Source id="1457966" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-30T00:00:00.000Z</StatusDate><Source id="1784315" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-06-30T00:00:00.000Z</StatusDate><Source id="1784315" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-02-01T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-03-15T00:00:00.000Z</StatusDate><Source id="1595804" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18693">Orion Corp</Company><Country id="XQ">Nordic countries</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-12-31T00:00:00.000Z</StatusDate><Source id="526757" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-19T00:00:00.000Z</StatusDate><Source id="1362396" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="504">Immune deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1700">Premature ovarian failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-03-30T00:00:00.000Z</StatusDate><Source id="1251723" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-15T00:00:00.000Z</StatusDate><Source id="1263001" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-15T00:00:00.000Z</StatusDate><Source id="1263001" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-15T00:00:00.000Z</StatusDate><Source id="1263001" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-15T00:00:00.000Z</StatusDate><Source id="1263001" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-15T00:00:00.000Z</StatusDate><Source id="1263001" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="504">Immune deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-06T00:00:00.000Z</StatusDate><Source id="1151683" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-01T00:00:00.000Z</StatusDate><Source id="938960" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-05-01T00:00:00.000Z</StatusDate><Source id="901723" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-31T00:00:00.000Z</StatusDate><Source id="1101416" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="237252" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1700">Premature ovarian failure</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="938960" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-21T00:00:00.000Z</StatusDate><Source id="1384513" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-21T00:00:00.000Z</StatusDate><Source id="1384513" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-21T00:00:00.000Z</StatusDate><Source id="1384513" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-21T00:00:00.000Z</StatusDate><Source id="1384513" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1412341" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-01-01T00:00:00.000Z</StatusDate><Source id="1412341" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1991-10-28T00:00:00.000Z</StatusDate><Source id="1426496" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1989-03-01T00:00:00.000Z</StatusDate><Source id="1429807" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-01-01T00:00:00.000Z</StatusDate><Source id="1452697" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><Source id="1426496" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-09T00:00:00.000Z</StatusDate><Source id="1353046" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-09T00:00:00.000Z</StatusDate><Source id="1353046" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-09T00:00:00.000Z</StatusDate><Source id="1353046" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-15T00:00:00.000Z</StatusDate><Source id="1263002" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-15T00:00:00.000Z</StatusDate><Source id="1263002" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-15T00:00:00.000Z</StatusDate><Source id="1263002" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-15T00:00:00.000Z</StatusDate><Source id="1263002" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-02-15T00:00:00.000Z</StatusDate><Source id="1263002" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-09-15T00:00:00.000Z</StatusDate><Source id="1784316" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-09-15T00:00:00.000Z</StatusDate><Source id="1784316" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-09-15T00:00:00.000Z</StatusDate><Source id="1784316" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-09-15T00:00:00.000Z</StatusDate><Source id="1784316" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-09-15T00:00:00.000Z</StatusDate><Source id="1784316" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3127">Spinal and bulbar muscular atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-19T00:00:00.000Z</StatusDate><Source id="1947193" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-03-30T00:00:00.000Z</StatusDate><Source id="1251723" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3127">Spinal and bulbar muscular atrophy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-28T00:00:00.000Z</StatusDate><Source id="1963782" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-10-08T00:00:00.000Z</StatusDate><Source id="221091" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-10-08T00:00:00.000Z</StatusDate><Source id="221091" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="49">Breast tumor</Indication><Source id="190402" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><Source id="190402" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="IT">Italy</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-08-01T00:00:00.000Z</StatusDate><Source id="312610" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-02-01T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-02-01T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="113">Endometriosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1780">Uterine fibroids</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15931">TAP Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3247">Hormone dependent prostate cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1985-12-08T00:00:00.000Z</StatusDate><Source id="311700" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1233">Precocious puberty</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1994-12-31T00:00:00.000Z</StatusDate><Source id="1151681" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20300">Takeda Pharmaceutical Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="3127">Spinal and bulbar muscular atrophy</Indication><AwardedIndication>Treatment of spinobulbar muscular atrophy </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-02T00:00:00.000Z</MileStoneDate><Source id="1951513" type="SERIAL"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072507">AbbVie Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="1233">Precocious puberty</Indication><AwardedIndication>For the treatment of Central Precocious Puberty (CPP).</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-12-19T00:00:00.000Z</MileStoneDate><Source id="1362396" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072507">AbbVie Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="1233">Precocious puberty</Indication><AwardedIndication>For Central Precocious Puberty.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-22T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15931">TAP Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1233">Precocious puberty</Indication><AwardedIndication>Treatment of central precocious puberty</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-07-25T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00881"><Name>GNRH receptor</Name><SwissprotNumbers><Swissprot>O18821</Swissprot><Swissprot>O42329</Swissprot><Swissprot>P30968</Swissprot><Swissprot>P30969</Swissprot><Swissprot>P32236</Swissprot><Swissprot>P32237</Swissprot><Swissprot>P49922</Swissprot><Swissprot>Q01776</Swissprot><Swissprot>Q8CH60</Swissprot><Swissprot>Q8SPZ1</Swissprot><Swissprot>Q95JG1</Swissprot><Swissprot>Q95MG6</Swissprot><Swissprot>Q95MH6</Swissprot><Swissprot>Q96P88</Swissprot><Swissprot>Q9MZI6</Swissprot><Swissprot>Q9TTI8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1010842">Norwood Immunology Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1072507">AbbVie Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18693">Orion Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="22711">AEterna Zentaris Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="29913">Ardana Bioscience Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="12">Patent - Non-Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>2</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O</Smiles><Smiles>CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@H](Cc5c[nH]cn5)NC(=O)[C@@H]6CCC(=O)N6</Smiles></StructureSmiles><Deals><Deal id="113539" title="Abbott and Takeda to comarket leuprorelin in North America, Latin America, Spain and Mexico through TAP joint venture"></Deal><Deal id="120502" title="Zentaris to develop 3- and 6-month depot formulations of Takeda's leuprorelin"></Deal><Deal id="120504" title="Orion to market Takeda's leuprorelin in Nordic countries"></Deal><Deal id="120505" title="Zentaris to divest leuprorelin to Ardana"></Deal><Deal id="121864" title="Wyeth to market Takeda's Prostap in the UK and Republic of Ireland"></Deal><Deal id="121916" title="TAP Pharmaceutical Products to license immunology intellectual property from Norwood Immunology"></Deal><Deal id="164141" title="Abbott to spin-out AbbVie to develop portfolio of pharmaceuticals and biologics"></Deal></Deals><PatentFamilies><PatentFamily id="1105081" number="WO-2010014176" title="Preparation method of biodegradable micro-particles containing drugs"></PatentFamily><PatentFamily id="1115914" number="WO-2011140607" title="A method of treatment and diagnosis"></PatentFamily><PatentFamily id="1173313" number="WO-2007143381" title="Microparticles and methods for production thereof"></PatentFamily><PatentFamily id="1208401" number="WO-00027193" title="Method for treating a patient with neoplasia by treatment with a gonadotropin releasing hormone analog"></PatentFamily><PatentFamily id="1215181" number="WO-2004098513" title="Nasal administration of the lh-rh analog leuprolide"></PatentFamily><PatentFamily id="1239012" number="WO-2004087102" title="A process for preparing a pharmaceutical active ingredient with high specific surface area"></PatentFamily><PatentFamily id="1242798" number="WO-2004100928" title="Injectable liposomal depots for delivering active ingredients"></PatentFamily><PatentFamily id="1275224" number="EP-00190833" title="Method For Producing Microcapsule"></PatentFamily><PatentFamily id="1282260" number="WO-00001403" title="Use Of Composition Comprising At Least One Substance Within The Group Gnrh-Analogues For Treatment Of Obsessive-Compulsive Disorder (Ocd)"></PatentFamily><PatentFamily id="1322262" number="CN-01865280" title="Solid phase polypeptide synthesis preparation method for leuprorelin"></PatentFamily><PatentFamily id="1403340" number="WO-2009148580" title="Controlled release copolymer formulation with improved release kinetics"></PatentFamily><PatentFamily id="1438303" number="WO-2005110369" title="Sustained-release microspheres and methods of making and using same"></PatentFamily><PatentFamily id="1474479" number="CN-101095941" title="New application of leuprorelin acetate in preventing and treating senile osteoporosis"></PatentFamily><PatentFamily id="1475511" number="WO-2007133020" title="A process of preparing microspheres for sustained release having improved dispersibility and syringeability"></PatentFamily><PatentFamily id="1577217" number="WO-09851325" title="Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods."></PatentFamily><PatentFamily id="1578666" number="WO-00003660" title="Biodegradable Compositions For The Controlled Release Of Encapsulated Substances"></PatentFamily><PatentFamily id="1581734" number="EP-00052510" title="Microencapsulation Of Water Soluble Polypeptides."></PatentFamily><PatentFamily id="1585503" number="WO-2004100882" title="Inhibition of drug binding to serum albumin"></PatentFamily><PatentFamily id="1621409" number="CN-101597325" title="A method for purifying leuprorelin"></PatentFamily><PatentFamily id="1622457" number="WO-2006101691" title="Therapy of prostate cancer with ctla4 antibodies and hormonal therapy"></PatentFamily><PatentFamily id="1627453" number="WO-2008044890" title="A method for preparing peptides using by solid phase synthesis"></PatentFamily><PatentFamily id="1684566" number="WO-09831346" title="Preparation Of Particles For Inhalation"></PatentFamily><PatentFamily id="1684937" number="WO-09933449" title="Beneficial Agent Delivery System With Membrane Plug"></PatentFamily><PatentFamily id="169649" number="WO-09800157" title="Aqueous formulations of peptides."></PatentFamily><PatentFamily id="169650" number="WO-09800158" title="Non-aqueous polar aprotic peptide formulations."></PatentFamily><PatentFamily id="172124" number="WO-00024374" title="Controlled release liquid delivery compositions with low initial drug burst"></PatentFamily><PatentFamily id="1759896" number="EP-00145240" title="Method for producing microcapsule"></PatentFamily><PatentFamily id="1775186" number="CN-101538315" title="A method for preparing leuprorelin by combination of a solid phase method and a liquid phase method"></PatentFamily><PatentFamily id="1796909" number="WO-09613290" title="Device For Aerosolized Delivery Of Peptide Drugs"></PatentFamily><PatentFamily id="1798187" number="EP-00839525" title="Sustained-release preparation"></PatentFamily><PatentFamily id="1800515" number="WO-09101126" title="Biodegradable system for regenerating the periodontium"></PatentFamily><PatentFamily id="1810878" number="EP-01803454" title="Treatment of cancer by a combination of non-ionizing radiation and androgen deprivation"></PatentFamily><PatentFamily id="1832685" number="WO-2008055112" title="Methods of treating autism and autism spectrum disorders"></PatentFamily><PatentFamily id="1852465" number="WO-2011128015" title="Cannula device and method and device for providing a cannula device with an implant"></PatentFamily><PatentFamily id="1903906" number="WO-09722357" title="Methods For Treating Prostate Cancer With Lhrh Antagonists"></PatentFamily><PatentFamily id="1914195" number="WO-03074023" title="Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect"></PatentFamily><PatentFamily id="1916857" number="WO-2006071208" title="Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of a GnRH"></PatentFamily><PatentFamily id="1945044" number="EP-00668073" title="Polyester Matrix For A Pharmaceutical Sustained-Release Preparation."></PatentFamily><PatentFamily id="1959320" number="WO-2008017664" title="Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatement of hormone-dependent cancers and corresponding pharmaceutical kits"></PatentFamily><PatentFamily id="1997368" number="US-06506410" title="Sustained release microparticle and method for preparing the same"></PatentFamily><PatentFamily id="1999568" number="WO-2010126036" title="Combined drug"></PatentFamily><PatentFamily id="200198" number="WO-2008100532" title="Low burst poly-(lactide/glycolide) and methods to produce polymers"></PatentFamily><PatentFamily id="2031576" number="WO-2006119388" title="Methods for production of peptide derivatives"></PatentFamily><PatentFamily id="2036298" number="WO-2009037401" title="System for controlled release of an active principle and method for preparation"></PatentFamily><PatentFamily id="2051448" number="WO-00102428" title="Process For The Preparation Of Lh-Rh Derivatives"></PatentFamily><PatentFamily id="2055104" number="WO-09715285" title="Non-Polymeric Sustained Release Delivery System"></PatentFamily><PatentFamily id="2135973" number="KR-2004066548" title="Locally administrable, sustained-release microsphere for biological active peptide and method for preparing the same"></PatentFamily><PatentFamily id="2144496" number="CN-101407540" title="A solid phase synthesis method of leuprorelin"></PatentFamily><PatentFamily id="2166329" number="US-05446025" title="Formulations and method of the percutaneous administration of leuprolide."></PatentFamily><PatentFamily id="217805" number="CN-01969821" title="Anticancer release agent simultaneously carrying anticancer medicament and synergist agent"></PatentFamily><PatentFamily id="2217813" number="WO-2009114959" title="Injectable sustained-release pharmaceutical formulation and method for preparing it"></PatentFamily><PatentFamily id="2242869" number="WO-09413317" title="Sustained-Release Preparation"></PatentFamily><PatentFamily id="2250321" number="WO-03015820" title="Gnrh agonist combination drugs"></PatentFamily><PatentFamily id="2250519" number="WO-2007082726" title="Flowable leuprolide-containing composition for treating inflammation-mediated neurodegenerative diseases"></PatentFamily><PatentFamily id="2255448" number="WO-2007107328" title="Subcutaneous implants containing a degradation-resistant polylactide polymer"></PatentFamily><PatentFamily id="2275806" number="EP-00779072" title="Production of microspheres"></PatentFamily><PatentFamily id="2323574" number="WO-00202144" title="Medicinal preparations for treating sex hormone-dependent diseases"></PatentFamily><PatentFamily id="2352104" number="US-03914412" title="(Des' Gly)+0 10 -Gn' Rh Nonapeptide Amide Analogs In Position 6 Having Ovulation-Inducing Activity."></PatentFamily><PatentFamily id="2357715" number="CN-101099859" title="New use of leuprorelin acetate in delaying aging and preventing menopause syndrome"></PatentFamily><PatentFamily id="2375048" number="US-20120128683" title="Autism treatment"></PatentFamily><PatentFamily id="2440760" number="WO-2013003487" title="Device, system and methods for the oral delivery of therapeutic compounds"></PatentFamily><PatentFamily id="2456853" number="CN-102863517" title="Goserelin purification method"></PatentFamily><PatentFamily id="2474216" number="US-06261584" title="Sustained delivery of an active agent using an implantable system."></PatentFamily><PatentFamily id="2506097" number="WO-00050012" title="Solid oral dosage form containing an enhancer"></PatentFamily><PatentFamily id="257872" number="WO-2008077027" title="Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders"></PatentFamily><PatentFamily id="2666498" number="WO-2014010614" title="Method for manufacturing microcapsule powder"></PatentFamily><PatentFamily id="2686962" number="CN-103446041" title="Leuprorelin slow-controlled drug release stick and preparation method thereof  "></PatentFamily><PatentFamily id="2799892" number="WO-2014142653" title="Vaccination composition"></PatentFamily><PatentFamily id="2857513" number="WO-09937288" title="Lyophilization Method For Sustained-Release Preparations"></PatentFamily><PatentFamily id="288557" number="WO-2004016083" title="Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy"></PatentFamily><PatentFamily id="2959288" number="US-09150615" title="Process for the preparation of leuprolide and its pharmaceutically acceptable salts"></PatentFamily><PatentFamily id="2970886" number="US-09918665" title="Transdermal porator and patch system and method for using same"></PatentFamily><PatentFamily id="3046074" number="WO-2015152704" title="Pharmaceutical system for the oral administration of sensitive therapeutic substances"></PatentFamily><PatentFamily id="3080076" number="US-20150347677" title="Method and system for designing polynucleotide sequences and polynucleotide sequences obtained thereby"></PatentFamily><PatentFamily id="3093144" number="KR-2015136085" title="Vaccination composition."></PatentFamily><PatentFamily id="3137148" number="CN-105330726" title="Synthesis method of leuprorelin"></PatentFamily><PatentFamily id="3216791" number="CN-105646670" title="Synthesis process of leuprorelin"></PatentFamily><PatentFamily id="3219715" number="CN-105622727" title="A method of combining compound leuprorelin by solid phase and liquid phase combination"></PatentFamily><PatentFamily id="326180" number="WO-03002092" title="Controlled release composition and method of producing the same"></PatentFamily><PatentFamily id="3267826" number="CN-105797134" title="A poorly leuprorelin sustained-release preparation"></PatentFamily><PatentFamily id="3268334" number="CN-105796501" title="A pyrantel pamoate bright preparation method of alarelin slow release preparation"></PatentFamily><PatentFamily id="327995" number="WO-2005048989" title="Excipients in drug delivery vehicles"></PatentFamily><PatentFamily id="331068" number="WO-2007059921" title="Solution-phase synthesis of leuprolide and its intermediates"></PatentFamily><PatentFamily id="3344598" number="CN-105535933" title="Subcutaneous injectable implants of leuprolide"></PatentFamily><PatentFamily id="3345728" number="CN-105237762" title="Peg leuprorelin"></PatentFamily><PatentFamily id="3443393" number="CN-106038492" title="Preparation method for preparing slow release leuproreline microsphere"></PatentFamily><PatentFamily id="3476557" number="CN-106146622" title="Leuprolide acetate industrialized preparation method"></PatentFamily><PatentFamily id="349122" number="CN-101195653" title="Solid-liquid synthesizing method for leuprorelin"></PatentFamily><PatentFamily id="3589473" number="CN-106518979" title="A synthesis preparation method for leuprorelin"></PatentFamily><PatentFamily id="3648524" number="CN-106668831" title="A preparation method of leuprorelin microsphere"></PatentFamily><PatentFamily id="3804523" number="CN-107163106" title="Method for purifying leuprorelin acetate crude product"></PatentFamily><PatentFamily id="385678" number="WO-08905632" title="Porous Microspheres For Drug Delivery And Methods For Making Same"></PatentFamily><PatentFamily id="3896134" number="JP-2017226618" title="Transdermal formulation of leuprorelin"></PatentFamily><PatentFamily id="3907145" number="WO-2018005618" title="Tripartite combination therapy for prostate cancer"></PatentFamily><PatentFamily id="3934212" number="CN-107573408" title="A synthesis method of high purity leuprorelin"></PatentFamily><PatentFamily id="398613" number="US-04211769" title="Preparations For Vaginal Administration"></PatentFamily><PatentFamily id="4040800" number="WO-00230393" title="Polymeric delivery formulations of leuprolide with improved efficacy"></PatentFamily><PatentFamily id="419165" number="JP-2010001248" title="The sustained-release millimeter of leuprorelin acetate, a microcapsule"></PatentFamily><PatentFamily id="431091" number="WO-2005074896" title="Sustained release preparation"></PatentFamily><PatentFamily id="4419511" number="WO-2019043174" title="Pharmaceutical combinations for the treatment of cancer"></PatentFamily><PatentFamily id="4443085" number="WO-2019058273" title="Pharmaceutical compositions for delivery of peptide"></PatentFamily><PatentFamily id="4477323" number="CN-109593118" title="Liquid phase synthesizing method for leuprorelin"></PatentFamily><PatentFamily id="453685" number="EP-00202065" title="Polymer, production and use thereof"></PatentFamily><PatentFamily id="4562538" number="WO-2019125358" title="Pharmaceutical compositions having a selected release duration"></PatentFamily><PatentFamily id="4563328" number="US-20190192614" title="Method of producing leuprolide microsphere and use"></PatentFamily><PatentFamily id="465113" number="EP-00781548" title="Production of sustained-release preparation for injection"></PatentFamily><PatentFamily id="479976" number="WO-2008075762" title="Sustained-release composition and method for producing the same"></PatentFamily><PatentFamily id="593251" number="WO-2011148384" title="Novel process for the preparation of leuprolide and its pharmaceutically acceptable salts thereof"></PatentFamily><PatentFamily id="615266" number="US-04008209" title="Nonapeptide Amide Analogs Of Luteinizing Releasing Hormone."></PatentFamily><PatentFamily id="652760" number="WO-2005117830" title="Liquid depot formulations"></PatentFamily><PatentFamily id="662238" number="WO-2008015232" title="Subcutaneous implants releasing an active principle over an extended period of time"></PatentFamily><PatentFamily id="687434" number="WO-09800152" title="Non-aqueous protic peptide formulations"></PatentFamily><PatentFamily id="701644" number="WO-2008112283" title="Androgen responsiveness profiling"></PatentFamily><PatentFamily id="722725" number="EP-00586238" title="Method of producing sustained-release microcapsules"></PatentFamily><PatentFamily id="830064" number="EP-00442671" title="Prolonged release microcapsules"></PatentFamily><PatentFamily id="843087" number="EP-01151748" title="Continuous manufacturing procedure of microcapsules for extended release of water soluble peptides"></PatentFamily><PatentFamily id="84485" number="CN-102464702" title="Method for preparing leuprorelin acetate, product and application"></PatentFamily><PatentFamily id="864574" number="WO-09606598" title="Aerosol drug formulations containing polyglycolyzed glycerides."></PatentFamily><PatentFamily id="87811" number="EP-00171907" title="Copolymer And Method For Producing The Same"></PatentFamily><PatentFamily id="910912" number="US-03997516" title="Method For Protecting Guanidino Group And Restoring The Same"></PatentFamily><PatentFamily id="917620" number="WO-02087616" title="Preventives for postoperative recurrence of premenopausal breast cancer"></PatentFamily><PatentFamily id="935115" number="WO-2006004167" title="Sustained-release composition, process for producing the same and use of the same"></PatentFamily><PatentFamily id="941074" number="WO-09521611" title="Compositions comprising a mast cell degranulation-blocking agent for treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin."></PatentFamily><PatentFamily id="946111" number="WO-2004100927" title="Injectable depots consisting of liposomal aggregates for the delivery of active substances"></PatentFamily><PatentFamily id="984789" number="US-04005194" title="Treatment Of Prostatic Hyperplasia"></PatentFamily><PatentFamily id="992515" number="WO-2004078160" title="New process for the production of implants"></PatentFamily><PatentFamily id="993208" number="WO-2005067889" title="Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a GnRH"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>21</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astellas Pharma Inc" id="1013295"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="TOLMAR Holding Inc" id="1050057"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Debiopharm SA" id="15620"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ipsen" id="17259"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novelion Therapeutics Inc" id="19180"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Stolle Research &amp; Development Corp" id="20258"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"></CompanyLink><CountAsOwner>27</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>28</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Kentucky" id="20600"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="FUJIFILM Wako Pure Chemical Corporation" id="20785"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tulane University" id="22292"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AEterna Zentaris Inc" id="22711"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MediGene AG" id="24224"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ferring Pharmaceuticals SA" id="29708"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ardana Bioscience Ltd" id="29913"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nagoya Industrial Science Research Institute" id="31708"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fukuyama University" id="DOL1000376"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oakwood Laboratories LLC" id="DOL1000546"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>